Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine | Zendy

Dilpreet Singh | Zendy; Leila Muhieddine | Zendy; Douglas Einstadter | Zendy; Stanley P. Ballou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine

Author(s) -

Dilpreet Singh,

Leila Muhieddine,

Douglas Einstadter,

Stanley P. Ballou

Publication year - 2019

Publication title -

rheumatology advances in practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 4

ISSN - 2514-1775

DOI - 10.1093/rap/rkz009

Subject(s) - medicine , hydroxychloroquine , maculopathy , incidence (geometry) , population , retinopathy , retrospective cohort study , pediatrics , ophthalmology , surgery , diabetes mellitus , disease , endocrinology , physics , environmental health , covid-19 , infectious disease (medical specialty) , optics

HCQ-induced macular toxicity is rare in routine clinical practice, seems to require prolonged HCQ therapy (>18 years) and is not necessarily associated with functional visual loss. Our findings suggest that co-morbid conditions that are common in RA and SLE contribute substantially to vision loss and should not be ignored.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research